25.06.2026
US prescription drug spending is forecast to exceed $560bn in 2026 as demand for GLP-1 obesity and diabetes treatments continues to rise.
01.06.2026
Stay updated on the South African retail pharmacy scene as Clicks and Dis-Chem battle it out with innovative strategies for consumer loyalty.
30.10.2024
Aspen Pharmacare has secured a licensing agreement to enter the GLP-1 agonist market, positioning it for growth in diabetes and obesity treatment solutions.
24.10.2024
Novo Nordisk's share price dropped 19% amidst growing competition from Eli Lilly in the diabetes and weight-loss drug market.